Generic-drug maker Watson Pharmaceuticals started off its November with a bang: beating third-quarter estimates, hitting a new high on the stock market and starting a new life as a transformed company. Late on Oct. 31, Watson (WPI) announced it has closed its $5.9 billion acquisition of Swiss partner Actavis, making it the world's third-largest generic-drug maker after Teva Pharmaceutical Industries (TEVA) and Novartis (NVS) unit Sandoz. The firm